Fisher & Paykel Healthcare is a respiratory care device company globally, selling their products and systems in over 90 countries worldwide. They offer a broad range of products and systems in respiratory and acute care and the treatment of obstructive sleep apnea (OSA). They supply both the hospital and homecare markets.
Fisher & Paykel entered the respiratory care market in 1971 with the development of a unique respiratory humidifier system for use in critical care. The company headquarters are located in Auckland, New Zeland. Their products are manufactured in New Zealand and Mexico.
Fisher & Paykel's Optiflow™ product for Nasal High Flow therapy is being utilized by affected hospitals to treat patients and is being considered by others as they prepare for the potential further impact.
Nasal High Flow has been recognized by the World Health Organization (WHO) for the treatment of patients with COVID-19 with airborne precautions. The WHO refers to the usage of Nasal High Flow therapy for pre-oxygenation before intubation and for non-invasive respiratory support with close monitoring for clinical deterioration in selected patients with hypoxemic respiratory failure.
Vice President – Products & Technology
Vice President - Quality & Regulatory Affairs
Vice President - Human Resources
General Manager – Supply Chain
Managing Director & Chief Executive Officer
Chief Financial Officer
Vice President Corporate
Senior Vice President – Sales & Marketing
Vice President - Information & Communication Technology
Vice President – Surgical Technologies
Documentaries, videos and podcasts
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.